Abbreviations
- Ab:
-
Antibody
- ACT:
-
Adoptive cellular transfer
- ADCC:
-
Antibody-dependent cellular cytotoxicity
- ATG:
-
Anti-thymocyte globulin
- BTN3A1:
-
Butyrophilin 3A1
- CAR:
-
Chimeric antigen receptor
- CIMT:
-
Association for Cancer Immunotherapy
- CIP:
-
CIMT Immunoguiding Program
- CT:
-
Cancer–testis
- CTLA-4:
-
Cytotoxic T-lymphocyte-associated protein 4
- CTL:
-
Cytotoxic T lymphocytes
- CTX:
-
Cyclophosphamide
- DNAM-1:
-
DNAX Accessory Molecule-1
- FasL:
-
Fas ligand
- IFA:
-
Incomplete Freud’s adjuvant
- IL-10:
-
Interleukin 10
- LP:
-
Long peptides
- PD-1:
-
Programmed cell death 1
- PD-L1:
-
Programmed death-ligand 1
- PGE2:
-
Prostaglandin E2
- RRG:
-
CIMT Regulatory Research group
- SP:
-
Short peptides
- Teff:
-
T effector cells
- TERS:
-
TCR-engineered reference samples
- TIGIT:
-
T cell immunoreceptor with Ig and ITIM domains
- Treg:
-
T regulatory cells
- VEGF-A:
-
Vascular endothelial growth factor A
Acknowledgments
The authors would like to thank Christiane Wellié-Reeve (Mainz, Germany) for carefully proof reading the meeting report. Selected sessions of the CIMT meeting were made possible by research grants from the German Bundesministerium für Bildung and Forschung (BMBF Grant: 031A018). The CIMT working group CIP receives support for educational activities by the Wallace Coulter Foundation (Florida, USA).
Conflict of interest
The authors declare that they have no conflict of interest. Cedrik M. Britten has been the co-organizer of the meeting. Björn-Philipp Kloke has been the co-organizer of the CIMT Endeavour workshop.
Author information
Authors and Affiliations
Corresponding author
Additional information
This meeting report is a summary of presentations from the Twelfth Annual Meeting of the Association for Cancer Immunotherapy, CIMT 2014, published together with a series of Focussed Research Reviews based on lectures given at the conference.
Rights and permissions
About this article
Cite this article
Kloke, BP., Mahr, A., Jabulowsky, R.A. et al. Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6–8, 2014. Cancer Immunol Immunother 64, 923–930 (2015). https://doi.org/10.1007/s00262-014-1643-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-014-1643-7